What hematology is researching now
The topics gaining the most ground, ranked by the PubDaily Trend Score: new research, stronger evidence, new trials and new guidelines. 291 topics in 22 specialties, updated 18 Oct 2026.
Monthly reportThe fastest-rising topics in medicine: October 2026Read →Bispecific antibodies in myeloma
Teclistamab, elranatamab and talquetamab in multiple myeloma.
Measurable residual disease
Detecting residual disease after treatment of blood cancers.
Gene therapy for sickle cell and thalassaemia
CRISPR-based and lentiviral gene therapies for haemoglobin disorders.
CAR-T in blood cancers
Chimeric antigen receptor T-cell therapy in lymphoma, myeloma and leukaemia.
Key point: CAR T-cell therapy has emerged as an effective option for refractory or progressive mantle cell lymphoma after prior covalent BTK inhibitor treatment.
Immune thrombocytopenia
ITP and its newer treatments.
Key point: Adult ITP care incorporates newer thrombopoietin receptor agonists and small molecule kinase inhibitors, emphasizing thrombotic risk and quality of life.
DOACs in cancer-associated thrombosis
Direct oral anticoagulants for venous thromboembolism in people with cancer.
See all 13 hematology topics
Every rising topic, with the papers behind it. Free for doctors.
How the Trend Score works
Four signals
Growth in new papers (35%), growth in randomised trials, meta-analyses and systematic reviews (25%), new clinical trials registered (20%), and new guidelines and consensus statements (20%), each over the last 12 months against the 12 before.
A score out of 100
Each signal is ranked against every topic we follow, so a score of 90 means the topic is ahead of about 90% of them. Rising fast: 80 and above. Rising: 55 to 79. Emerging: fewer than 100 papers the year before, too few to rank.
What it does not tell you
More research on a topic is not evidence that a treatment works. Open a topic to read the papers and guidelines themselves. Counts come from PubMed and ClinicalTrials.gov.